Chen R D
Cancer Institute, Chinese Academy of Medical Sciences, Beijing.
Zhonghua Zhong Liu Za Zhi. 1993 Jul;15(4):272-4.
Patients with cervical precancerous lesions were double blindly divided into 2 groups and treated with either Retinamide II (RII) or Riboflavin (VB2) suppository. The suppository containing RII 20mg or VB2 5mg was given intravaginally daily for 100 days, divided into 2 courses. Clinical examination, papanicolaou cytology and tissue biopsy under colposcope were carried out before and after treatment. The results showed that the disappearance rates of precancerous lesions (DRPL) after the second course of treatment with RII or VB2 were 68.5% and 52.00%, and the overall response rates were 74.29% and 56.0%, respectively. 1 or 2 yrs after treatment, DRPL of the RII, Riboflavin and laser groups did not show significant difference (P > 0.05). The statistically significant differences were among the RII, Riboflavin, laser groups and antiphlogistic treatment group (P < 0.01). The results indicate that local application of RII and Riboflavin may serve as chemopreventive agents for cervical cancer.
宫颈癌前病变患者被双盲分为两组,分别用维甲酸II(RII)或核黄素(VB2)栓剂治疗。含20mg RII或5mg VB2的栓剂每天阴道给药,共100天,分两个疗程。治疗前后进行临床检查、巴氏细胞学检查和阴道镜下组织活检。结果显示,RII或VB2第二个疗程治疗后癌前病变消失率(DRPL)分别为68.5%和52.00%,总有效率分别为74.29%和56.0%。治疗后1或2年,RII、核黄素和激光组的DRPL无显著差异(P>0.05)。RII、核黄素、激光组与抗炎治疗组之间差异有统计学意义(P<0.01)。结果表明,局部应用RII和核黄素可作为宫颈癌的化学预防剂。